Epidyolex (cannabidiol) GB Prescribing Information
Adverse events should be reported. Healthcare Professionals are asked to report any suspected adverse events via their national reporting system.
For the UK, reporting forms and information can be found at
or search for Yellow Card MHRA in the Google Play or Apple App Store.
Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com
touchSYMPOSIUM HIGHLIGHTS Sharing perspectives: Specific DEEs through the lens of a paediatric and an adult neurologist
Symposium presentations by three leading experts in epilepsy, who discuss management requirements for specific DEEs, the clinical evolution of DEEs from childhood to adulthood and the seizure–non-seizure equilibrium of symptoms.
By clicking on the link yellowcard.mhra.gov.uk you will be leaving the touchneurology.com website which is neither owned nor controlled by Jazz Pharmaceuticals. Jazz Pharmaceuticals is not responsible for the content of this third party website
Setting the scene: Understanding the complexity of developmental and epileptic encephalopathies (DEEs)
A whole-patient approach to DEE management: A paediatric neurologist’s perspective
Are DEEs for adult neurologists too?
A whole-patient approach to DEE management: An adult neurologist’s perspective
Adverse Events
Adverse Events
By clicking on the link yellowcard.mhra.gov.uk you will be leaving the touchneurology.com website which is neither owned nor controlled by Jazz Pharmaceuticals. Jazz Pharmaceuticals is not responsible for the content of this third party website
Overview & Learning Objectives
Overview
Beyond seizures, developmental and epileptic encephalopathies (DEEs) are associated with many cognitive, behavioural, motor, psychiatric and sleep-related comorbidities, which persist into adulthood.1,2 Therefore, treating these comorbidities, in addition to seizure aspects of disease is crucial for maintaining quality of life, preventing complications and preserving independence, mobility and working in adulthood.2,3 Additionally, it is critical to consider how DEEs should be managed in adulthood, as adult patients may present with a broader range of clinical phenotypes and be under recognised compared with children.4-6
In this activity, leading experts discuss management requirements for specific DEEs, the clinical evolution of DEEs from childhood to adulthood and the seizure–non-seizure equilibrium of symptoms.
References
- Strzelczyk A, Schubert-Bast S. Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies. CNS Drugs. 2022;36(10):1079–1111.
- Samanta D. Management of Lennox-Gastaut syndrome beyond childhood: A comprehensive review. Epilepsy Behav. 2021;114(Pt. A):107612.
- Cross JH, Auvin S, Falip M, et al. Expert opinion on the Management of Lennox-Gastaut syndrome: Treatment algorithms and practical considerations. Front Neurol. 2017;8:505.
- Andrade DM,Berg AT, Hood V, et al. Dravet syndrome: A quick transition guide for the adult neurologist. Epilepsy Res. 2021;177:106743.
- Peron A, Canevini MP, Ghelma F, et al. Healthcare transition from childhood to adulthood in tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178(3):355–364.
- Selvarajah A, Zulfiqar-Ali Q, Marques P, et al.A systematic review of adults with Dravet syndrome. Seizure. 2021;87:39–45.
Learning Objectives
After watching this activity, participants should be better able to:
- Provide an overview of the disease landscape and broad management requirements for patients with DEEs
- Consider the clinical evolution of specific DEEs from childhood to adulthood, and discuss the need to periodically re-assess a patient’s diagnosis
- Examine the perspectives of paediatric and adult physicians on the seizure–non-seizure equilibrium when managing LGS, DS and TSC using Epidyolex® (cannabidiol)
Faculty & Disclosures
Dr Peter Widdess-Walsh
Department of Neurology, The National Neuroscience Centre at Beaumont Hospital Dublin, Dublin, Ireland
Dr Peter Widdess-Walsh is a consultant neurologist at The National Neuroscience Centre at Beaumont Hospital Dublin. He trained in neurology and epilepsy at the renowned Cleveland Clinic and is US Board Certified in Neurology, Epilepsy and Clinical Neurophysiology. He specialises in seizures and epilepsy and has over 80 peer-reviewed publications in journals and books.
Speaker’s fees from Jazz Pharmaceuticals and Angelini.
Dr Kerstin Alexandra Klotz
Department of Neuropaediatrics and Muscle Disorders, University of Bonn, Bonn, Germany
Dr Alexandra Klotz is paediatric neurologist at the University of Bonn. She is also a fellow of the Berta Ottenstein program, a three year research fellowship. Dr Klotz clinical as well as scientific work is the management of rare and difficult to treat epilepsies in children. Her main research interests are in the treatment of epilepsy and comorbidities in patients with hypothalamic hamartoma and other epilepsies. Dr Klotz is member of the European Reference Network EpiCARE and of the Freiburg Center of rare diseases. She is also a principal investigator on several clinical trials to advance the development of new treatment options for children with drug-resistant epilepsies
Lectures and advice: Eisai, Jazz Pharmaceuticals, Neuraxpharm, UCB and Zogenix
Dr Antonietta Coppola
Department of Neuroscience, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Naples, Italy
Dr Antonietta Coppola is Assistant Professor of Neurology at the Department of Neuroscience, Reproductive and Odontostomatological Sciences at the University of Naples Federico II, Italy. She is a member of the Italian chapter of the International League Against Epilepsy (ILAE). Her main area of expertise is the diagnosis and treatment of genetically determined epilepsies. She has authored around 100+Â peer-reviewed articles and book chapters, and serves on the editorial boards of several scientific journals.
Honoraria for participation in advisory boards, pharmaceutical industry-sponsored symposia, events and consultancy from: Jazz Pharmaceuticals, UCB and Eisai.